Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong tells Proactive's Andrew Scott she's delighted with what the interim data has revealed in their ongoing randomised Phase 2 study of HER-Vaxx in gastric cancer. It's shown positive overall survival with a Hazard Ratio of 0.418. The median overall survival for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8 months in patients treated with chemotherapy alone. Chong says they're now assessing how best to take development of the drug forward.
Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'
Quick facts: Imugene Ltd
Price: 0.115 AUD
Market Cap: $545.21 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE